Full-Time

Scientist 1

Upstream Process Development

Posted on 5/12/2025

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

Compensation Overview

$110k - $130k/yr

San Diego, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Data Analysis
Requirements
  • BS, MS, or PhD degree in applicable scientific field.
  • Minimum of 9 years directly related experience with a BS degree; Minimum of 6 years directly related experience with an MS degree; Minimum of 0 years’ experience with a PhD degree.
  • Knowledge and skill of mammalian cell cultures and concepts of cell metabolism, protein production, and characterization.
  • Knowledge and skill in relation to cell culture process steps including cell banking, thaw and expansion, and production (batch-fed and perfusion).
  • Knowledge of designing of experiments for increase productivity in relation to operation of multivariate experiments using the Sartorius platform ambr250 and stir tank vessels.
  • Skill and knowledge of scaling up to 500 L or more in single-use technologies.
  • Knowledge of quantitative and qualitative analytical methods and interpretation of analytical data.
  • Ability to organize workload, oversee direct reports, and relevant resource requirements.
  • Skill in leadership duties, to include time management and planning.
  • Knowledge of products manufacturing following SOPs, batch records and working within a cGMP regulated environment.
  • Ability to observe technical issues with troubleshooting knowledge of process and equipment problems.
  • Ability to operate complex systems and equipment and optimize their use in manufacturing in accordance with defined goals.
  • Knowledge of specific product-related operations in protein purification.
  • Ability to mentor and train purification associates and leads in process transfer, scale-up, from scientific and engineering perspective.
Responsibilities
  • Executes assigned work with full understanding of and ability to apply principles, theories, and concepts in specialized areas of responsibility.
  • Uses current scientific literature with the technical capability to select methods and techniques for obtaining solutions within broadly defined practices and procedures.
  • Produces proteins using mammalian cell culture to support lead generation/optimization and preclinical studies.
  • Produces proteins using mammalian cell cultures under cGMP standards and with cGMP standards and regulations in consideration for production of clinical trial materials.
  • Participates in technical transfer of upstream manufacturing processes from clients and between Development and Manufacturing groups.
  • Leads client projects including the planning, execution, and conclusions.
  • Exercises technical discretion in design, execution and interpretation of manufacturing and production that contributes to project goals.
  • Provides detailed observations, analyzes data, interprets results and develops scientifically-sound solutions.
  • Acts as a Subject Matter Expert (SME) to train others in areas of expertise. Assists and offers guidance to the Process Development group and Manufacturing group as necessary to train on correlated processes.
  • Oversees production schedules, materials, equipment and manpower requirements.
  • Maintains records to comply with regulatory requirements and assists with in-process testing.
  • Operates and ensures appropriate maintenance of production equipment as it relates upstream production activities.
  • Troubleshoots processing problems, bringing unusual problems (e.g., potential deviations) to the attention of the supervisor.
  • Initiates deviations, assess product quality impact, and propose Corrective and Preventative Actions (CAPA), as needed.
  • Sets up and performs scale down models to assist with process validations and manufacturing investigations, providing analysis as needed.
  • Prepares technical reports, summaries, protocols, batch records and performs quantitative analyses.
  • Uses professional concepts in accordance with company objectives to solve complex problems in creative and effective ways.
  • Organizes own daily workload schedule and relevant resource requirements.
  • Operates with minimal supervision on complex systems and equipment.
  • Mentors and leads the work of junior personnel in the field. Provides training to new personnel in specific technical processes.
  • Supports project teams on multiple projects simultaneously.
  • Represents departmental activities as needed, including project teams, task forces, audits and business or technical meetings with outside groups.
  • Develops effective working relationships with both internal and external partners.
  • Operates to the highest ethical and moral standards.
  • Complies with Abzena's policies and procedures.
  • Communicates effectively with clients, supervisors, colleagues and staff.
  • Participates effectively as a team player in all aspects of Abzena's business.
  • Adheres to quality standards set by regulations and Abzena policies, procedures, and mission.
  • Performs other duties as assigned.

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Geoffrey M. Glass appointed CEO July 22, 2025, drives growth.
  • Dr. Moncef Slaoui joins board January 8, 2025, boosts innovation.
  • Scientific Advisory Board formed May 15, 2025, guides ADC strategies.

What critics are saying

  • Lonza acquires Halo Life Science March 17, 2026, steals ADC share.
  • WuXi Biologics launches 10 ADC technologies Q1 2026, undercuts ThioBridge®.
  • FDA warning letter halts Bristol PA trials January 15, 2026.

What makes Abzena unique

  • ThioBridge® platform creates stable, effective ADCs for clients.
  • Composite Human Antibody™ reduces immunogenicity in biologics.
  • AbZelectPRO™ launches GS knockout CHO-K1 for afucosylated proteins.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth

Abzena
Apr 24th, 2025
Abzena's Customer Archetype Therapeutics to Present at AACR 2025 on Lung Cancer Drug Candidate Results

Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.

INACTIVE